Remedium Bio announces the publication of preclinical data demonstrating the performance of its adjustable dose gene therapy platform – Prometheus™
Posted:
Prometheus™ was specifically designed as a subcutaneously injected gene delivery system, utilizing the same route of administration as most current therapeutic biologics. Remedium is applying the Prometheus™ platform technology to the development of its lead candidate RMD1202, a single injection disease-modifying treatment for type 2 diabetes and obesity.
Akeso, a Chinese biotech that made headlines for beating Merck’s Keytruda in a head-to-head trial, won approval in China this week for the therapy, a company spokesperson confirmed to STAT. New data show early hints of the medicine improving patient…
From detecting TB, cancer, and heart attacks to diagnosing patients with strokes and diabetes, Artificial Intelligence (AI) is redefining the healthcare system across the world. Currently, more than 90% of hospitals and healthcare systems have implemented an AI or automation strategy,…
Attendees
Sponsors and Exhibitors
AI In Healthcare: A Virtual Course
Contact us